about

Risen Pharma

A clinical stage group with innovative drug research and development capability and international competitiveness

Committed to clinical urgent, patient accessible drug R&D and commercialization. The Group has two R&D centers (with a total square footage of nearly 9000m²), which are located in the hub of Shanghai Zhangjiang Hi-Tech Park and Suzhou Industrial Park, and invested in the construction of a manufacturing site covering 55 acres of land in the Life Blue Bay of Lingang,. The Group has nearly 20 new drug research and development pipelines, focusing on drug R&D in the three core therapeutic areas of orthopedics, oncology and neuroscience, and dedicated R&D investment in the field of siRNA.

Risen Pharma

A clinical stage group with innovative drug research and development capability and international competitiveness

Corporate Culture

People-centered

To serve the patients, Risen built a team as the driving force for innovation. With the strong support of investors, together with partners and suppliers, we are committed to providing doctors with diversified therapeutics to benefit human beings.

Team

Doctor

Investor

Partners

Supplier

Patient

Accept Challenges Pursue Excellence Persist in innovation Technological innovation first R&D efficiency first People development first

Development History

2015

2019

2020

2021

2022

2023

2024

2025

2026

2015.07

Incorporation of the Company

2015.08

Series A Funding - RMB 53.6 million

2015.12

Suzhou Lab Opens

2019.02

Risen-TopAlliance Cooperation - RMB 300 million

2019.07

Executives from Orthopedics and Clinical Medicine Join.

2019.10

Suzhou Lab Undergoes Two Expansions

2020.05

Executives from Drug Development and Pharmaceutical Chemistry Join.

2020.07

RP903 FDA P-IND

2020.12

RP901 CDE IND

2020.12

B Round Funding - RMB 374 Million

2021.03

RP901 Clinical Phase I SAD

2021.09

Acquisition of 56 mu of land in Lingang Area

2021.10

RP902 CDE P-IND

2021.12

RP903 CDE P-IND

2021.12

RP901 FDA IND

2022.03

RP903 CDE IND

2022.05

RP901 临床I期 MAD

2022.06

RP904 CDE P-IND

2022.06

RP903 FDA IND

2022.06

首席科学官CSO、生物高管加入

2022.06

张江研发中心竣工

2023.2

First in China: ANGPTL3 siRNA drug
clinical trial

2023.2

RP904 tablets have obtained approval for clinical trials from the NMPA.

2023.3

Risen was entitled as a "special and innovative" small to medium-sized

2023.4

China's first ANGPTL3 siRNA drug is approved for clinical trials

2023.6

Secondary Biological Safety Laboratory (BSL-2) successfully registered

2023.12

Ranks on the "2023 Hurun Global Cheetah Enterprise List

2024.8

PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.

2024.8

Risen and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.

2024.8

Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.

2025.3

AACR 2025 | Risen Pharma Two Innovative Research Achievements Shine

2025.4

AACR 2025 | Risen Pharma Unveils Global First Data from Its Research Studies

2025.5

Risen Pharma Announces Publication of Research on KRAS G12D PROTAC Candidate RP03707 in the Journal of Medicinal Chemistry

2026.6

Risen Pharma Successfully Holds National Investigator Meeting for Phase II Clinical Trial of RP902 in Mild Cognitive Impairment Due to Alzheimer's Disease

2026.7

Clinical Update | Risen Pharma Announces First Patient Enrolled in Phase II Clinical Trial of RP902 in China

R&D Manangement Team

Jiasheng Lv, Ph.D.

Founder、CEO

Details

Xianqi Kong, Ph.D.

Senior Vice President

Details

Ying Huang, Ph.D.

Senior Vice President，Chemistry

Details

Tianlun Zhou, Ph.D.

Vice President, Biology

Details

Liang Sha

Vice President, Clinical Research

Details

Emma Saffman, Ph.D.

Vice President，Intellectual property

Details

Partners

The joint R&D of small molecule drugs by TopAlliance and Risen in the field of anti-tumor therapy complements the small molecule anti-tumor drug development pipeline of TopAlliance, while conducive to the exploration of Mab drug combination therapy in the future.

RP901 tablets are a potential First-in-class small molecule drug with independent intellectual property rights in the field of osteoarthritis (OA) treatment. Maiwei Biotech, the partner, is an innovative biopharmaceutical company with a full industry chain layout, and has already launched two drugs in the orthopedic field. We look forward to working with Maiwei Biotech to transform this exciting scientific achievement into innovative therapeutic drugs that will benefit patients in China.

Jiasheng Lv, Ph.D.

Founder、CEO

With nearly 15 years of drug research experience, Dr. Lv has led a number of Class 1 innovative drug projects and is an inventor of several clinical drug compounds. Among them, the new drug project for Alzheimer's disease is in phase III clinical research in the United States (orphan drug, fast-track approval). The individual currently holds the positions of a doctoral supervisor at the School of Life Sciences, Fudan University, and a researcher at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

Xianqi Kong, Ph.D.

Senior Vice President

With nearly 30 years of drug research and development experience, hundreds of international patents, Dr. Kong has wealth of intellectual property application, protection experience. He previously served as Director of Pharmacy at Bellus Health Inc. (TSX:BLU), a publicly traded Canadian biotechnology company, and was the first inventor of several clinical experimental compounds.

Ying Huang, Ph.D.

Senior Vice President，Chemistry

With over 25 years of drug discovery experience, I have led or contributed to the discovery of 10+ NCEs. I spearheaded the advancement of the first-in-class EED inhibitor MAK683 from early-stage screening to first-in-human trials within 4.5 years. My expertise spans multiple technology platforms, including small molecules, protein degraders, molecular glues, and ADC.

Tianlun Zhou, Ph.D.

Vice President, Biology

With nearly 30 years of drug research and development experience, especially in RNA drugs and anti-HBV drug R&D, Dr. Zhou is proficient in medicine, cancer epidemiology, molecular biology, data mining and pathway analysis and other fields. He was previously head of antiviral drug development and translational cancer research at Novartis.

Liang Sha

Vice President, Clinical Research

With nearly 20 years of drug development experience. He/she has held key R&D roles in both large/medium-sized multinational corporations and domestic innovative start-ups, with a strategic focus on drug development in the central nervous system (CNS) and rare disease areas. Since 2009, he/she has been deeply engaged in Alzheimer's disease. His/her career spans product development strategy, clinical trial design and execution, regulatory submissions, and in-licensing/out-licensing activities. He/she has established comprehensive clinical development and pharmacovigilance systems for multiple companies, and has successfully passed inspections by the NMPA and provincial authorities with zero deficiencies on multiple occasions. Several products under his/her leadership have been successfully launched and marketed.